Skip to main content

Table 1 Baseline characteristics

From: Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure

 

Total (N = 40)

Increased eGFR (N = 26)

No-increased eGFR (N = 14)

P value

Age, years

68 (57–75)

68 (55–72)

71 (61–79)

0.177

Male, N

29 (73)

19 (73)

10 (71)

0.911

Body weight, kg

62 (51–73)

66 (54–76)

54 (47–71)

0.112

Body mass index, kg/m2

23.9 (19.6–27.2)

24.7 (21.9–27.9)

20.4 (19.0–24.9)

0.076

Systolic blood pressure, mmHg

108 (95–119)

110 (100–119)

100 (90–120)

0.173

Heart rate, beats per minutes

70 (63–81)

69 (63–83)

74 (64–79)

0.570

HbA1c, %

6.8 (6.6–7.6)

6.7 (6.6–7.7)

7.0 (6.6–7.2)

0.776

Fasting blood sugar, mg/dL

110 (96–129)

102 (86–128)

122 (107–130)

0.076

Left ventricular ejection fraction, %

42 (27–56)

39 (28–58)

42 (26–55)

0.966

Ischemic etiology, N

19 (48)

12 (46)

7 (50)

0.816

Atrial fibrillation, N

8 (20)

5 (19)

3 (21)

0.868

Hemoglobin, g/dL

12.9 (11.5–15.6)

13.6 (16.0–11.7)

12.4 (11.1–14.2)

0.223

Hematocrit, %

38.5 (34.2–44.9)

40.6 (35.2–45.6)

37.6 (33.5–41.4)

0.192

Serum albumin, g/dL

3.7 (3.5–3.8)

3.7 (3.5–3.9)

3.6 (3.2–3.7)

0.107

Serum sodium, mEq/L

138 (136.3–140)

139.5 (137.8–140)

137 (134.5–140.3)

0.094

Serum potassium, mEq/L

4.4 (4.1–4.6)

4.4 (4.1–4.6)

4.4 (4.2–4.5)

0.943

eGFR, mL/minute/1.73m2

53.0 (36.1–74.5)

54.5 (40.0–73.5)

50.1 (31.6–80.4)

0.712

Plasma BNP, pg/mL

94 (54–251)

86 (50–175)

205 (75–374)

0.059

Plasma NT-proBNP, pg/mL

864 (260–1819)

740 (251–1424)

1479 (356–3057)

0.242

Heart failure therapies

Beta-blockers, N

37 (93)

23 (89)

14 (100)

0.186

ACEI/ARB, N

37 (93)

26 (100)

11 (79)

0.014

Loop diuretics, N

19 (48)

11 (42)

8 (57)

0.370

Furosemide, mg/day

0 (0–20)

0 (0–20)

20 (0–40)

0.158

MRA, N

27 (68)

17 (65)

10 (71)

0.697

Thiazides, N

2 (5)

2 (8)

0 (0)

0.287

Statin, N

30 (75)

20 (77)

10 (71)

0.702

Anti-diabetic agents

Sulfonylureas, N

3 (8)

2 (8)

1 (7)

0.950

DPP-4i, N

20 (50)

14 (54)

6 (43)

0.741

Biguanides, N

8 (20)

5 (19)

3 (21)

0.868

Insulin, N

5 (12)

5 (19)

0 (0)

0.079

  1. Continuous variables were expressed as median (25%-75% percentile) and categorical variables were expressed as number (%)
  2. HbA1c, glycated hemoglobin; eGFR, estimated glomerular filtration rate; BNP, b-type natriuretic peptide; NT-proBNP, N-terminal pro-b-type natriuretic peptide; ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonists; DPP-4i, dipeptidyl peptidase-4 inhibitors